157 related articles for article (PubMed ID: 37142293)
41. Risk of malignancy in patients with inflammatory bowel disease: A population-based cohort study from China.
Zhang H; Zhang M; Chen X; Guo M; Zhou R; Lv H; Li Y; Tan B; Li J; Xu H; Zheng W; Yang H; Qian J
Int J Cancer; 2022 Jun; 150(11):1770-1778. PubMed ID: 35037241
[TBL] [Abstract][Full Text] [Related]
42. Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease.
Andersson P; Karling P
Ups J Med Sci; 2022; 127():. PubMed ID: 35140875
[TBL] [Abstract][Full Text] [Related]
43. Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy.
Taborelli M; Sozzi M; Del Zotto S; Toffolutti F; Montico M; Zanier L; Serraino D
PLoS One; 2020; 15(6):e0235142. PubMed ID: 32574216
[TBL] [Abstract][Full Text] [Related]
44. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
[TBL] [Abstract][Full Text] [Related]
45. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study.
Jess T; Horváth-Puhó E; Fallingborg J; Rasmussen HH; Jacobsen BA
Am J Gastroenterol; 2013 Dec; 108(12):1869-76. PubMed ID: 23978954
[TBL] [Abstract][Full Text] [Related]
46. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe.
Lakatos PL; Lovasz BD; David G; Pandur T; Erdelyi Z; Mester G; Balogh M; Szipocs I; Molnar C; Komaromi E; Golovics PA; Vegh Z; Mandel M; Horvath A; Szathmari M; Kiss LS; Lakatos L
J Crohns Colitis; 2013 Jun; 7(5):385-91. PubMed ID: 22766526
[TBL] [Abstract][Full Text] [Related]
47. Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study.
Eriksson C; Henriksson I; Brus O; Zhulina Y; Nyhlin N; Tysk C; Montgomery S; Halfvarson J
Aliment Pharmacol Ther; 2018 Sep; 48(6):638-645. PubMed ID: 30069892
[TBL] [Abstract][Full Text] [Related]
48. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
[TBL] [Abstract][Full Text] [Related]
49. Risk of Urolithiasis in Patients With Inflammatory Bowel Disease: A Nationwide Danish Cohort Study 1977-2018.
Dimke H; Winther-Jensen M; Allin KH; Lund L; Jess T
Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2532-2540.e2. PubMed ID: 33007511
[TBL] [Abstract][Full Text] [Related]
50. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark.
Burisch J; Jess T; Egeberg A
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2704-2712.e3. PubMed ID: 30936024
[TBL] [Abstract][Full Text] [Related]
51. Inflammatory bowel diseases in Faroese-born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development.
Hammer T; Lophaven SN; Nielsen KR; von Euler-Chelpin M; Weihe P; Munkholm P; Burisch J; Lynge E
Aliment Pharmacol Ther; 2017 Apr; 45(8):1107-1114. PubMed ID: 28176348
[TBL] [Abstract][Full Text] [Related]
52. Risk and clinical characteristics of lymphoma in Korean patients with inflammatory bowel diseases: a multicenter study.
Park SK; Ye BD; Lee C; Im JP; Kim YH; Kim SO; Byeon JS; Myung SJ; Yang SK; Kim JH
J Clin Gastroenterol; 2015 Feb; 49(2):e11-6. PubMed ID: 24705089
[TBL] [Abstract][Full Text] [Related]
53. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
Hong SN; Kim HJ; Kim KH; Han SJ; Ahn IM; Ahn HS
Aliment Pharmacol Ther; 2017 Jan; 45(2):253-263. PubMed ID: 27933686
[TBL] [Abstract][Full Text] [Related]
54. Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort.
van den Heuvel TR; Wintjens DS; Jeuring SF; Wassink MH; Romberg-Camps MJ; Oostenbrug LE; Sanduleanu S; Hameeteman WH; Zeegers MP; Masclee AA; Jonkers DM; Pierik MJ
Int J Cancer; 2016 Sep; 139(6):1270-80. PubMed ID: 27170593
[TBL] [Abstract][Full Text] [Related]
55. Risk of cancer in patients with inflammatory bowel disease and venous thromboembolism: a nationwide cohort study.
Sørensen GV; Erichsen R; Svaerke C; Farkas DK; Sørensen HT
Inflamm Bowel Dis; 2012 Oct; 18(10):1859-63. PubMed ID: 22241668
[TBL] [Abstract][Full Text] [Related]
56. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
57. Risk of lymphoma in inflammatory bowel disease.
Loftus EV; Tremaine WJ; Habermann TM; Harmsen WS; Zinsmeister AR; Sandborn WJ
Am J Gastroenterol; 2000 Sep; 95(9):2308-12. PubMed ID: 11007233
[TBL] [Abstract][Full Text] [Related]
58. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort.
Ashworth LA; Billett A; Mitchell P; Nuti F; Siegel C; Bousvaros A
Inflamm Bowel Dis; 2012 May; 18(5):838-43. PubMed ID: 21887728
[TBL] [Abstract][Full Text] [Related]
59. Increased Risk of Cancer and Mortality in a Large French Population-Based Paediatric-Onset Inflammatory Bowel Disease Retrospective Cohort.
Dupont-Lucas C; Leroyer A; Ley D; Spyckerelle C; Bertrand V; Turck D; Savoye G; Maunoury V; Guillon N; Fumery M; Sarter H; Gower-Rousseau C;
J Crohns Colitis; 2023 Apr; 17(4):524-534. PubMed ID: 36316987
[TBL] [Abstract][Full Text] [Related]
60. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study.
Vos AC; Bakkal N; Minnee RC; Casparie MK; de Jong DJ; Dijkstra G; Stokkers P; van Bodegraven AA; Pierik M; van der Woude CJ; Oldenburg B; Hommes DW;
Inflamm Bowel Dis; 2011 Sep; 17(9):1837-45. PubMed ID: 21830262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
